



copy

RECEIVED

SEP 04 2002

AM100341

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mark R. Schmitt, et al.

Serial No.: 09/895,975

Group Art Unit: 1645

Filed: June 29, 2001

Examiner:

Confirmation No.: 9267

For: Substituted-Triazolopyridines as Anticancer Agents

August 29, 2002

Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

TRANSMITTAL OF SUPPLEMENTARY INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR(1.97(b)(3))

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU238370638US addressed to the Commissioner for Patents, Box DD, Washington, DC 20231.

August 30, 2002
Date

Daniel B. Moran
Daniel Moran

Transmitted herewith is a Supplementary Information Disclosure Statement for the above-identified application that is being mailed before the mailing date of a first office action on the merits. This Supplemental Information Disclosure Statement is to provide the Examiner with a copy of :

U.S. PATENT NUMBERS

US4444774A	J.P. Dusza, et al.	04-24-1984
------------	--------------------	------------

FOREIGN PATENT DOCUMENTS

DD55956A	E. Tenor, et al.	1967	
DD55956A	E. Tenor, et al.	1967	English Abstract
DD61269A	E. Tenor, et al.	1968	
DD61269A	E. Tenor, et al.	1968	English Abstract
EP0305093A	Simon Teanby Hodgson	03-01-1989	
JP02212488	S. Shimizu	08-23-1990	
JP02212488	S. Shimizu	08-23-1990	English Abstract
JP56110620	Mochida Pharmaceutical	11-01-1981	
JP56110620	Mochida Pharmaceutical	11-01-1981	English Abstract
FR2784380A	Waldemar Franz Pfengle	04-14-2000	
FR2784380A	Waldemar Franz Pfengle	04-14-2000	English Abstract

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

A.P. NOVIKOVA, ET AL., Khim-Farm. ZH., Vol. 15, No. 4, 1981, Pages 31-35
A.P. NOVIKOVA, ET AL., Khim-Farm. ZH., Vol. 15, No. 4, 1981, Pages 31-35 English Abstract
T. OKABAYASHI, Chem. Pharm. Bull., Vol. 8., No. 2, 1960, Pages 162-167
M. SUIKO, ET AL., Sgric. Biol. Chem., Vol. 41, No. 10, 1977, Pages 2047-2053
PCT INTERNATIONAL SEARCH, PCT/USO1/20672, 31/07/2002

The Commissioner is hereby authorized to charge any additional fee due as required under 37 CFR 1.16 or 1.17 by this paper to Deposit Account No. 01-1425. Two additional copies of this sheet are enclosed.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Daniel B. Moran". The signature is fluid and cursive, with the first name "Daniel" being more prominent.

Daniel B. Moran
Registration No. 41,204
Patent Agent

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940-0874
Tel. No. 845-602-2224



09-03-02

Docket No: AM100341

Patent

1645
#4
9/9/02
82IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re of Application of: Mark R. Schmitt, et. al.
Serial No.: 09/895,975 ✓
Filed: June 29, 2001 ✓
For: Substituted-Triazolopyridines as Anticancer Agents ✓
Confirmation No.: 9267
Customer Number: 25291

Group Art No.: 1645
Examiner:
TECH CENTER 1600/2900

SEP 04 2002

Commissioner for Patents
Washington, DC 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT1. Preliminary Statements

In accordance with 37 CFR 1.97 and 1.98, Applicants submit herewith patents, publications, or other information of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR 1.56. This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) the information is material to the examination of this application; (iii) additional information material to the examination of this application does not exist; (iv) the information, protocols, results and the like reported by third parties are accurate or enabling; or (v) the information constitutes prior art to the subject invention.

CERTIFICATE OF MAILING 37 CFR §1.10

I hereby certify that this paper and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date written below in an envelope as "Express Mail Post Office to Addressee" Mailing Label Number EU238370638US addressed to the Commissioner for Patents, Washington, DC 20231.

Date

August 30, 2002

Daniel B. Moran

2. Identification of Time of Filing

This Information Disclosure Statement

- a. ☐ is filed within three months of the filing date of the application.
- b. ☒ is filed before the mailing date of a first Office Action on the merits.
- c. ☐ is filed before the mailing date of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.
- d. ☐ is filed after the period specified in 2(a), 2(b) or 2(c) above, but before the mailing date of a final action under 37 CFR 1.311. This statement includes a certification under 37 CFR 1.97(e) or the fee set forth in 37 CFR 1.17(p).
- e. ☐ is filed after the mailing date of a final action or Notice of Allowance but before payment of the issue fee. This statement includes (i) a certification under 37 CFR 1.97(e), and (ii) the fee set forth in 37 CFR 1.17(p).

3. ☒ Certification under 37 CFR 1.97(e) and 1.704(d)
The undersigned attorney certifies

- a. ☒ that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement, or
- b. ☐ that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the statement.
- c. ☐ The undersigned attorney certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign application patent office in a counterpart foreign application and was not received by any individual designated in 37 CFR 1.56(c) more than thirty (30) days prior to the filing of the statement.

☒ Newly Cited Information
A legible copy of the patents, publications or other information cited on the attached form PTO 1449 is enclosed, except that no copy of a pending U.S. application is enclosed.

☐ Previously Cited Information
No copy of the patents, publications or other information cited on the attached form PTO-1449 is enclosed because it has been previously cited by or submitted to the Office in a prior application which is relied upon for an earlier filing date under 35 USC 120.
Prior application is Serial Number _____, filed on _____ of _____ for _____.

- ☒ Concise Explanation
Documents cited above which are not in the English Language
- a. ☐ have been explained in the specification.
- b. ☒ have an abstract (or other concise explanation) in English enclosed or if readily available a translation into English of the document is enclosed.

Form PTO-1449 is enclosed in duplicate.

- ☐ Fees
- ☐ Fee for filing under 37 CFR 1.97(c) or (d) Fee: \$180.00

Method of Payment of Fees:

Charge Deposit Account No. 01-1425 in the amount of \$0.00

A duplicate of this statement is enclosed.

Instructions as to Overpayment/Underpayment:


Credit any overpayment and charge any underpayment to Deposit Account No. 01-1425.



Daniel B. Moran

Reg. No. 41,204

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (845) 602-2224



Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	100341
		Filing Date	June 29, 2001
		First Named Inventor	Mark R. Schmitt
		Group Art Unit	1645
		Examiner Name	
Sheet 1 of 1		Attorney Docket Number	AM100341

RECEIVED

SEP 04 2002

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number (If known)	Kind Code (If Known)			
	1.	US4444774A		J.P. Dusza, et al.	04-24-1984	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (If Known)				
	2.		DD55956A		E. Tenor, et al.	1967		
	3.		DD55956A		E. Tenor, et al.	1967	English Abstract	
	4.		DD61269A		E. Tenor, et al.	1968		
	5.		DD61269A		E. Tenor, et al.	1968	English Abstract	
	6.		EP0305093A		Simon Teanby Hodgson	03-01-1989		
	7.		JP02212488		S. Shimizu	08-23-1990		
	8.		JP02212488		S. Shimizu	08-23-1990	English Abstract	
	9.		JP56110620		Mochida Pharmaceutical	11-01-1981		
	10.		JP56110620		Mochida Pharmaceutical	11-01-1981	English Abstract	
	11.		FR2784380A		Waldemar Franz Pfrengle	04-14-2000		
	12.		FR2784380A		Waldemar Franz Pfrengle	04-14-2000	English Abstract	<input type="checkbox"/>

OTHER PRIOR ART — NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	13.	A.P. NOVIKOVA, ET AL., Khim-Farm. ZH., Vol. 15, No. 4, 1981, Pages 31-35	
	14.	A.P. NOVIKOVA, ET AL., Khim-Farm. ZH, Vol. 15, No. 4, 1981, Pages 31-35, ENGLISH ABSTRACT	
	15.	T. OKABAYASHI, Chem. Pharm. Bull., Vol 8, No. 2, 1960, Pages 162-167	
	16.	M. SUIKO, ET AL., Sgric. Biol. Chem., Vol. 41, No. 10, 1977, Pages 2047-2053	
	17.	PCT INTERNATIONAL SEARCH, PCT/USO1/20672, 31/07/2002	<input type="checkbox"/>

Duplicate

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.